Free Trial
OTCMKTS:GNBT

Generex Biotechnology (GNBT) Stock Price, News & Analysis

Generex Biotechnology logo

About Generex Biotechnology Stock (OTCMKTS:GNBT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
60,924 shs
Market Capitalization
$73,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Receive GNBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generex Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

GNBT Stock News Headlines

Bloomage Biotechnology
Who’s really running America
Most Americans have never heard his name… He was instrumental in Trump’s victory. He turned J.D. Vance from a Trump-hater into his vice president. He’s one of the driving forces behind the rise of cryptocurrencies, digital commerce, social media, Big Data, cloud computing, and artificial intelligence... In other words, he’s America’s puppet master.
Generex Creates Own Regulatory Reality
Generex Plans Reverse Stock Split
Generex Biotechnology Jumps
See More Headlines

GNBT Stock Analysis - Frequently Asked Questions

Shares of GNBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Generex Biotechnology investors own include SELLAS Life Sciences Group (SLS), (UNISQ) (UNISQ), Amgen (AMGN), VBI Vaccines (VBIV), Novavax (NVAX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

Today
4/28/2025
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:GNBT
Employees
15
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.66 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
79,094,000
Market Cap
$73,000.00
Optionable
Not Optionable
Beta
-0.07

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:GNBT) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners